Toward ICD-11 Implementation: Attitudes and Expectations of the Russian Psychiatric Community

Effect of cariprazine on the 6 domains of schizophrenia in ICD-11: a narrative review

One of the innovations in the ICD-11 section "schizophrenia and other primary psychotic disorders" is the implementation of 6 additional domains, which should improve the diagnosis and treatment of these conditions. Cariprazine is a new atypical antipsychotic with a predominant affinity for D3 receptors, which is registered in Russia for the treatment of schizophrenia, mania, mixed and depressive episodes in bipolar I disorder. In modern algorithms for the treatment of schizophrenia with the dominance of negative disorders, pharmacotherapy is recommended to start with cariprazine, as the drug that has the best evidence base in the treatment of the ICD-11 "negative symptoms" domain. Cariprazine has been shown to be effective against the symptoms of the ICD-11 "positive symptoms" domain and can be considered the drug of choice in the treatment of first and multiple episodes of illness, disorganized thinking and disturbed behavior in the form of aggression. The pro-cognitive effect of cariprazine has been proven in nonclinical and clinical studies, where it developed independently of other symptoms within the ICD-11 domain "cognitive symptoms" and exceeded the similar effect of a number of other antipsychotics. The use of cariprazine in individuals with moderate to severe ICD-11 domain "manic symptoms" may be justified in view of its evidence-based anti-manic efficacy in bipolar I disorder, although it does not offer advantages over other anti-manic antipsychotics. The efficacy of cariprazine in schizophrenic patients with severe symptoms of the ICD-11 domain "depressive symptoms" needs additional research, since, on the one hand, it has not shown its effectiveness in comparison with placebo in relation to "depressive" PANSS items, but is registered for the treatment of bipolar depression. In the treatment of symptoms of the ICD-11 domain "psychomotor symptoms", the use of monotherapy with cariprazine, as well as other antipsychotics, is less justified, since the emphasis is on other types of therapy.